ERp27 Inhibitors

Chemical inhibitors of ERp27 include a variety of protease inhibitors that target the protein's functional role in the endoplasmic reticulum. E-64 is a potent cysteine protease inhibitor that directly interferes with the active site of ERp27, preventing it from cleaving substrates and thereby directly inhibiting its function. Similarly, Leupeptin serves as a dual inhibitor of serine and cysteine proteases, effectively obstructing ERp27's ability to participate in the proteolytic pathways it is involved in. Pepstatin A, while classically an aspartyl protease inhibitor, also contributes to the inhibition of ERp27 by disrupting its role in protein processing within the endoplasmic reticulum, where ERp27 is known to operate.

Further contributing to the inhibition of ERp27, MG-132 acts as a proteasome inhibitor, leading to the accumulation of misfolded proteins that otherwise would be degraded. This accumulation can overwhelm ERp27's capacity to assist in protein folding, thereby inhibiting its function. Lactacystin, another proteasome inhibitor, operates under a similar mechanism by increasing the levels of misfolded proteins and stressing the protein-folding environment that ERp27 helps to maintain. AEBSF, a serine protease inhibitor, prevents the proteolytic activation of proteins within the ER, thereby reducing the functional demand on ERp27. Calpain inhibitors such as ALLN, PD150606, and MDL-28170 contribute to the inhibition of ERp27 by stabilizing the cellular proteostasis network, which in turn lowers the requirement for ERp27's chaperone activity. AAF-CMK and the cysteine protease inhibitors Z-LLF-CHO and Z-LLL-CHO directly inhibit ERp27 by binding to its active site, which effectively blocks the protein's substrate cleavage and folding functions. These chemical inhibitors collectively target and inhibit the functional pathways ERp27 is known to be part of, leading to its inhibition.